Close Menu

This article has been updated with additional information from Roche's earnings call. 

NEW YORK (GenomeWeb) – Roche on Thursday reported a 3 percent increase in sales of its diagnostics division in 2019, driven primarily by its immunodiagnostic solutions, which are part of its Centralized and Point of Care Solutions business.

Overall, Roche reported CHF 61.47 billion ($63.4 billion) in revenues for the year, up 9 percent at constant exchange rates from CHF 56.85 billion in 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

The New York Times reports that a new viral variant of concern has been identified in New York City.

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.